Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
NCT03863080 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RVT-1401
Study Locations (20)
California
- The Neurology Center of Southern California — Carlsbad
- UC Irvine - MDA ALS and Neuromuscular Center — Orange
- Care Access Research — Pasadena
New York
- Dent Institute — Amherst
- University of Buffalo — Buffalo
- Hospital for Special Surgery — New York
Ontario
- London Health Sciences Centre — London
- Ottawa Hospital Research Institute — Ottawa
- University Health Network Toronto General Hospital — Toronto
Alabama
- IMC/Diagnostic and Medical Clinic — Mobile
Arizona
- Phoenix Neurological Associates — Phoenix
Colorado
- CSNA — Colorado Springs
Connecticut
- Yale School of Medicine Department of Neurology — New Haven
Florida
- Neurological Services of Orlando — Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03863080
The ClinicalTrials.gov registry entry for NCT03863080 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunovant Sciences, which has 12 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03863080 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, New York, Ontario. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03863080 about?
NCT03863080 is a clinical study titled "A Study of RVT-1401 in Myasthenia Gravis (MG) Patients". The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compa...
What is the current status of trial NCT03863080?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2019-05-21. Estimated completion is 2020-12-21.
What conditions does trial NCT03863080 study?
This clinical trial studies the following conditions: Myasthenia Gravis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03863080?
The interventions under investigation include: Placebo (DRUG), RVT-1401 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03863080?
This trial is sponsored by Immunovant Sciences, which has 12 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03863080 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.